ARTICLE | Clinical News
M40403 regulatory update
February 11, 2008 8:00 AM UTC
EMEA's COMP granted Orphan Drug designation for M40403 to prevent oral mucositis in head and neck cancer patients receiving radiotherapy. ActivBiotics has completed Phase I testing with the superoxide...